Answers are grounded in this paper and cite their sources.
Metallo-β-lactamases (MBLs) threaten the clinical utility of β-lactam antibiotics by hydrolyzing penicillins, cephalosporins, and carbapenems. Moreover, they can also hydrolyze all clinically used inhibitors (e.g., clavulanic acid, sulbactam, and tazobactam) that protect β-lactam antibiotics from
No takes yet. Share an insight, caveat, or question.
Lohans et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: